SCHEMBL9909159

SCHEMBL9909159

N#Cc1cc(Cl)ccc1-c1nccc2ccc(C(=O)O)cc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.43
SLC22A12 Q96S37 1/20 0.40
SRD5A1 P18405 1/20 0.39
SRD5A2 P31213 1/20 0.39
CSNK2A2 P19784 1/20 0.38
CSNK2B P67870 1/20 0.38
KDM4C Q9H3R0 2/20 0.38
XDH P47989 2/20 0.38
KDM5B Q9UGL1 1/20 0.38
USP8 P40818 2/20 0.37
USP7 Q93009 2/20 0.37
TTR P02766 1/20 0.37
CDH1 P12830 1/20 0.37
APC P25054 1/20 0.37
CTNNB1 P35222 1/20 0.37
TCF7L2 Q9NQB0 1/20 0.37
USP47 Q96K76 1/20 0.37
KMO O15229 1/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9909212 0.87 NR1H4 (0.40) PLAUCSNK2A2CSNK2BKDM4CKDM4E
SCHEMBL9909260 0.85 HTR2B (0.44) PLAU
SCHEMBL9909158 0.84 KMT2A (0.46) PLAUSLC22A12KDM4CKDM4ERAB9A
SCHEMBL9907383 0.84 KDM4C (0.49) PLAUSRD5A1SRD5A2CSNK2A2CSNK2B
SCHEMBL9907375 0.82 KMO (0.53) PLAUSRD5A1SRD5A2CSNK2A2CSNK2B
SCHEMBL16502485 0.80 XDH (0.44) SLC22A12SRD5A1SRD5A2XDHTTR
SCHEMBL9907395 0.79 PLAU (0.43) PLAUSRD5A1SRD5A2CSNK2A2CSNK2B
SCHEMBL9909227 0.77 SLC22A12 (0.47) PLAUSLC22A12CSNK2A2CSNK2BKDM4C
SCHEMBL28943021 0.74 ESR1 (0.40) SLC22A12KDM4CXDH
SCHEMBL9907382 0.73 PLAU (0.47) PLAUSLC22A12KDM4CKDM5BTTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E PLAU 3322/4885SLC22A12 1751/4885SRD5A1 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.